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A shortcut to high-affinity Ga-68 and Cu-64
radiopharmaceuticals: one-pot click chemistry
trimerisation on the TRAP platform†
Zsolt Baranyai,a Dominik Reich,b Adrienn Vágner,a Martina Weineisen,b Imre Tóth,a
Hans-Jürgen Westerb and Johannes Notni*b
Due to its 3 carbonic acid groups being available for bioconjugation, the TRAP chelator (1,4,7-triazacyclo-
nonane-1,4,7-tris(methylene(2-carboxyethylphosphinic acid))) is chosen for the synthesis of trimeric bio-
conjugates for radiolabelling. We optimized a protocol for bio-orthogonal TRAP conjugation via Cu(I)-
catalyzed Huisgen-cycloaddition of terminal azides and alkynes (CuAAC), including a detailed investi-
gation of kinetic properties of Cu(II)–TRAP complexes. TRAP building blocks for CuAAC, TRAP(alkyne)3
and TRAP(azide)3 were obtained by amide coupling of propargylamine/3-azidopropyl-1-amine, respect-
ively. For Cu(II) complexes of neat and triply amide-functionalized TRAP, the equilibrium properties as well
as pseudo-first-order Cu(II)-transchelation, using 10 to 30 eq. of NOTA and EDTA, were studied by UV-
spectrophotometry. Dissociation of any Cu(II)–TRAP species was found to be independent on the nature or
excess of a competing chelator, confirming a proton-driven two-step mechanism. The respective thermo-
dynamic stability constants (log KML: 19.1 and 17.6) and dissociation rates (k: 38 × 10
−6 and 7 × 10−6 s−1,
298 K, pH 4) show that the Cu(II) complex of the TRAP-conjugate possesses lower thermodynamic
stability but higher kinetic inertness. At pH 2–3, its demetallation with NOTA was complete within several
hours/days at room temperature, respectively, enabling facile Cu(II) removal after click coupling by direct
addition of NOTA trihydrochloride to the CuAAC reaction mixture. Notwithstanding this, an extrapolated
dissociation half life of >100 h at 37 °C and pH 7 confirms the suitability of TRAP-bioconjugates for appli-
cation in Cu-64 PET (cf. t1/2(Cu-64) = 12.7 h). To showcase advantages of the method, TRAP(DUPA-Pep)3,
a trimer of the PSMA inhibitor DUPA-Pep, was synthesized using 1 eq. TRAP(alkyne)3, 3.3 eq. DUPA-Pep-
azide, 10 eq. Na ascorbate, and 1.2 eq. Cu(II)-acetate. Its PSMA affinity (IC50), determined by the com-
petition assay on LNCaP cells, was 18-times higher than that of the corresponding DOTAGA monomer
(IC50: 2 ± 0.1 vs. 36 ± 4 nM), resulting in markedly improved contrast in Ga-68-PET imaging. In con-
clusion, the kinetic inertness profile of Cu(II)–TRAP conjugates allows for simple Cu(II) removal after click
functionalisation by means of transchelation, but also confirms their suitability for Cu-64-PET as demon-
strated previously (Dalton Trans., 2012, 41, 13803).
Introduction
Today, functional molecular imaging is an indispensable part
of personalised healthcare. Integrated scanners for simul-
taneous spatial mapping of morphology/anatomy as well as
functional aspects, such as metabolism or receptor expression,
have experienced a particularly dynamic evolution in recent
years. Their high value for medical diagnostics is rooted in an
outstanding superposition (registration) of functional and ana-
tomical images, allowing for precise localisation and func-
tional analysis of lesions and, subsequently, individual
planning of tailored therapies. While integration of functional
nuclear imaging, such as positron emission tomography (PET)
or single-photon emission computed tomography (SPECT),
with computed tomography (CT) has already become a clinical
standard,1 the new possibilities associated with the recent
combination of PET with magnetic resonance imaging (MRI)
into a full-body scanner have thrilled both researchers and
medical practitioners,2–4 not least because MRI can also provide
certain types of functional information. Since a comparable
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5dt00576k
aDepartment of Inorganic and Analytical Chemistry, University of Debrecen,
Egyetem tér 1, Debrecen, H-4032, Hungary
bLehrstuhl für Pharmazeutische Radiochemie, Technische Universität München,
Walther-Meissner-Strasse 3, D-85748 Garching, Germany.
E-mail: johannes.notni@tum.de; http://www.prc.ch.tum.de
This journal is © The Royal Society of Chemistry 2015 Dalton Trans.
Pu
bl
ish
ed
 o
n 
05
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 N
or
th
 D
ak
ot
a S
ta
te
 U
ni
ve
rs
ity
 o
n 
25
/0
5/
20
15
 0
9:
12
:2
4.
 
View Article Online
View Journal
progress is currently observed for small-animal imaging
devices, multimodal 3D-imaging becomes more and more
attractive for preclinical research and life sciences in general.
Here, optical methods,5 such as fluorescence/luminescence,6
Cerenkov7,8 or photoacoustic9 imaging, play an important role
as well, because the smaller size of investigated subjects is
compatible with the limited penetration depth of light. With
multi-purpose small animal scanners, meaningful and com-
pelling in vivo data can be obtained quickly, thus saving time
and money in medical and pharmaceutical development.
As the capabilities of functional imaging are primarily
determined by the performance and diversity of the corres-
ponding probes, efforts directed at suitable tracers have been
increased in recent time. In terms of PET tracers, this develop-
ment is further promoted by the fact that some medically
useful positron-emitting metal radionuclides have recently
become widely available, such as 89Zr,10 64Cu,11 and 68Ga.12,13
Of these, gallium-68 is particularly attractive for preclinical
and translational research, because it is obtained from
68Ge/68Ga-radionuclide generators with a very long shelf life
(up to 1 year).14–18 Such a generator can be eluted several times
a day, resulting in low radionuclide costs per experiment, par-
ticularly for high workload. Structures to be labelled are
usually conjugates of biomolecules with a chelator, into which
ionic 68GaIII is introduced simply by complex formation. Com-
pared to most traditional syntheses of 11C- or 18F-labelled com-
pounds, such one-step 68Ga-radiolabelling procedures are
generally fast (10–15 min) and quite similar for different com-
pounds. In almost all cases, slightly adjusted standard proto-
cols can be applied, for which purpose a wide range of
automated 68Ga-labelling modules (including technical
support) are commercially available.19 In other words, the key
challenge in making a 68Ga radiopharmaceutical consists in
synthesising the desired chelator conjugate as a precursor—for
the rest, out-of-the-box solutions are at hand.
In view of these prospects, recent years have seen a variety
of novel 68Ga chelators, optimised for efficient labelling and
facile bioconjugation.20–30 We proposed 1,4,7-triazacyclo-
nonane-1,4,7-tris(2-carboxyethyl-methylenephosphinic acid)
(TRAP, Scheme 1) as a suitable platform for elaboration of
68Ga radiopharmaceuticals.31–34 Apart from the fact that this
compound shows high efficiency in GaIII complexation35,36
and possesses unique selectivity for the GaIII ion,37 its sym-
metrical structure with three carboxylic acid moieties not
involved in complex formation allows for decoration with up to
three functional molecules, such as peptide receptor ligands,
fluorophors, other metal binding structures, etc.35,38–41 Hence,
TRAP is chosen for a straightforward design of radiolabelled
homo- or heteromultimeric conjugates, obviating the need for
branching linkers or additional multimeric scaffolds.
During the first few attempts to synthesise TRAP-based
multimeric conjugates by amide formation, it was observed that
common peptide coupling protocols, consisting of transform-
ation of carboxylates into active esters and subsequent reaction
with an amine, could not be applied without modification.
This is because active esters of TRAP are not stable in the long
term, which is probably related to the close proximity of the
phosphinate moieties. We found that the problem can be
solved by using excess amine and adding a uronium-type coup-
ling reagent as the last component.32 Clearly, this approach
prohibits the presence of certain functional groups in sub-
strates, particularly carboxylic acids and aliphatic alcohols.
Consequently, such substrates must be appropriately pro-
tected, which, at best, might be just inconvenient, but can also
turn out to be a rather complicated task. An obvious work-
around consists of using a different coupling chemistry. In a
proof-of-principle experiment employing the propargylamine
conjugate TRAP(alkyne)3 (Scheme 1), we have already shown
that the CuII-catalyzed 1,3-bipolar Huisgen-cycloaddition of
terminal alkynes and azides (commonly dubbed “click chem-
istry”)42 can be applied,35 with the major drawback being that
the reaction yields the copper complexes of the conjugates.
Although the copper ion could be removed from the chelate
cage with sulfide, this method spoiled the product with col-
loidal copper sulfide precipitates severely perturbing the
workup. Furthermore, sulfide is a reducing agent and cleaves
disulfide bridges, further limiting the method’s scope of appli-
cation. Another common method, the demetallation with
cyanide, is not attractive as well. The use of this highly toxic
reagent is disfavoured in the last synthetic step towards
pharmaceutical grade compounds, for it might complicate
release procedures in a GMP production setting because the
absence of traces of free cyanide had to be proven and certified
for each batch.
Since a solution for all these problems was expected to sub-
stantially expand the field of application for TRAP, and thus
pave the way towards a great variety of useful PET tracers, we
set out to establish a simple and robust protocol for click
chemistry functionalisation. As we focused on CuII removal by
transchelation and, therefore, kinetic inertness of CuII com-
plexes of TRAP, the results are also of immediate relevance for
64Cu-labelled TRAP radiopharmaceuticals and their applica-
bility. Moreover, our study might serve as a blueprint for conju-
Scheme 1 Structural formulae of TRAP and derivatives for functionali-
sation by means of CuI-catalyzed Huisgen 1,3-dipolar cycloaddition
(“Click chemistry”).
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gation reactions involving other chelator scaffolds intended to
be functionalised via click reactions.43
Results and discussion
The click reaction
Employing the model reaction of TRAP(alkyne)3 (Scheme 1)
with benzyl azide, a variety of reaction conditions were tested
in order to determine the optimum and limitations. CuII-
acetate was used in combination with a 10-fold excess of
sodium ascorbate for in situ formation of catalytically active
CuI. Other sources of CuII, such as CuSO4, were found suitable
as well, on the condition of complete solubility in the chosen
solvent system. Due to chelate formation with TRAP, more
than one equivalent of CuII is required in general; however, an
excess of more than 1.2 eq. provided no further advantage.
Complete interconversion of all alkyne sites was achieved with
a 10% excess of the azide component per alkyne (3.3 eq. in
total). This compares favourably to the amide functionalisa-
tion, which usually requires about 5 eq. of the respective
amine in order to obtain the trimeric conjugate only,32,44,45
and renders the click synthesis particularly attractive for valu-
able biomolecules. Furthermore, we found that the reaction
was completed after 30 min in many solvents, namely metha-
nol, ethanol, 2-propanol, DMSO, 1,4-dioxane, and aqueous
mixtures thereof. We noted that in pure acetonitrile, formation
of an emulsion was observed, resulting in an incomplete reac-
tion. This indicates the fact that solubility of all components,
that is, reactants and intermediates of the stepwise conju-
gation, is recommended to ensure a smooth reaction, render-
ing the choice of a solvent of key importance.
Altogether, the “click trimerisation” based on TRAP(alkyne)3
is best conducted using a small excess of azide (3.3 eq.) and
CuII (1.2 eq.), as well as a generous allowance of sodium
ascorbate (>10 eq.), and can be performed in a wide variety of
polar solvents or (aqueous) solvent mixtures. We found that
under optimal conditions (pure starting compounds, no pre-
cipitation of any component during the reaction), turnover is
virtually quantitative in less than one hour, and only the
trimer and traces of residual azide substrates are observed in
the reaction control (HPLC). Finally, we also prepared the
corresponding TRAP derivative with opposite Huisgen func-
tionality, TRAP(azide)3 (Scheme 1), to broaden the scope of the
method by enabling trimerisation of biological vectors with
alkyne groups as well.
Solution thermodynamics
Although the structure of any bifunctional chelator is changed
in the course of conjugation, the associated effects on thermo-
dynamic stability and kinetic inertness of metal complexes
often receive little attention. Apart from the obvious impact of
modifications directly on the chelating unit, such as the con-
version of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
acetic acid) to DOTA-monoamide46 upon synthesis of DOTA-
conjugates,47 conjugation on distal functional groups is widely
regarded to have no significant consequences.
However, since kinetic inertness of complexes is essentially
determined by competitive interaction of metal ions and
protons with the ligand’s donor atoms, we considered it to be
of relevance that TRAP possesses three carboxylates located
near the chelating moiety, acting as proton acceptors, which
are not present in the respective conjugates. Hence, thermo-
dynamic and kinetic studies were performed for TRAP as well
as for TRAP(CHX)3
32 (Scheme 2), serving as a model for tri-
meric TRAP conjugates.
The influence of conjugation becomes apparent upon com-
parison of the first protonation constants of the compounds
that characterise the protonation of the ring nitrogen (log K1
H,
see Table 1). While the value for TRAP (11.74) is smaller than
that for NOTA (12.16), TRAP(CHX)3 (10.92) is even less basic
but still ranges above EDTA (9.34). Since the protonation con-
stants characterising the most basic donor sites of ligands
(K1
H) generally correlate with thermodynamic stability con-
stants (KML) of their metal complexes, it comes as no surprise
that the respective values for the CuII complexes decrease in
the same order from Cu(NOTA) over Cu(TRAP) to Cu(TRAP
(CHX)3), possessing log KML values of 22.44, 19.09 and 17.63,
respectively (see Table 2). The same trend is observed for other
divalent metal ions, further substantiating the notion of a
different behaviour of TRAP and its conjugates.
The three macrocyclic chelators readily form CuII-complexes
in acidic solution (pH 1.5 and lower). Upon raising the pH, red
shifts of absorption maxima in VIS spectra were observed for
these compounds (for details see the ESI†), indicating similar
structural changes associated with certain protonation equili-
bria. Red and blue absorption shifts in CuII-complexes are
generally associated with ligand coordination and decoordina-
tion, respectively, in the axial position.50 Accordingly, known
solid state structures of CuII–NOTA complexes give rise to the
assumption that protonation of one axial carboxylate in N3O3-
hexacoordinate [Cu(NOTA)]− 51 results in de-coordination of
carboxylic acid, followed by formation of a [Cu(HNOTA)] struc-
ture comprising a pentacoordinate CuII centre with a tetra-
gonal-pyramidal geometry.52 In view of the comparable
Scheme 2 Structural formula of TRAP(CHX)3.
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changes in VIS spectra of NOTA and the phosphinate com-
plexes, we propose a similar structural change for the latter,
that is, a more or less complete de-coordination of one phos-
phonic acid upon protonation.
The involved species [Cu(TRAP(CHX)3)]
− and [Cu-
(H3TRAP))]
− exhibit protonation constants (log KH) of 1.97 and
1.58, respectively, revealing a similar basicity of the coordinat-
ing phosphinates among each other as well as in comparison
with those of the free chelators (1.55 and 1.50, see Table 1; a
complete list of experimentally determined protonation con-
stants of the complexes is given in the ESI†). Apparently, the
key process of side arm phosphinate protonation occurs at
comparable pH values for both complexes, because there is
only a relatively weak interaction between the phosphinate
oxygen donor atoms and CuII.
Kinetic inertness & transchelation
In order to establish a procedure for removal of CuII from
TRAP conjugates, we investigated transchelation of CuII
towards two chelators with known suitability for CuII coordi-
nation, namely EDTA and NOTA.52 Reactions were monitored
by means of UV spectrophotometry at the absorption bands of
Cu(EDTA) and Cu(NOTA) complexes over a pH range of 1.7–4,
using 10–30 eq. of EDTA or NOTA, and kinetic parameters
were calculated from these data (see the ESI†).
Fig. 1 shows that the obtained pseudo-first-order rate con-
stants at 298 K are independent from the identity or excess of
the competing chelator, and increase with decreasing pH. Con-
sequently, the transchelation is recognised as a three-step
process, initiated by protonation of the complex and followed
by its spontaneous dissociation as the rate-determining step,
thereafter free Cu2+ is captured quickly by the scavenger ligand
(Scheme 3). Such rationale is well in line with established con-
cepts, because, while transchelation from complexes of open-
Table 1 Protonation constants at 25 °C, determined in NaCl, I = 0.15 M. Literature data for Me4NCl, I = 0.1 M, are presented for comparison.
For TRAP and TRAP(CHX)3, equivalent protonations occurring at the second ring nitrogen and the first phosphinate oxygen are characterized by
log K5
H/log K6
H and log K2
H/log K3
H, respectively. NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid, EDTA = ethylenediamine-tetraacetic acid
TRAP(CHX)3 TRAP NOTA EDTA
NaCl NaCl Me4NCl
34 NaCl Me4NCl
48 NaCl Me4NCl
49
log K1
H 10.92(1) 11.74(3) 11.48 12.16(2) 13.17 9.34(1) 10.11
log K2
H 3.66(2) 5.46(2) 5.44 5.75(3) 5.74 6.12(1) 6.19
log K3
H 1.55(8) 4.80(2) 4.84 3.18(2) 3.22 2.85(2) 2.87
log K4
H — 4.16(2) 4.23 1.90(2) 1.96 2.18(2) 2.26
log K5
H — 3.49(2) 3.45 — — 1.77(2) —
log K6
H — 1.50(2) 1.66 — — — —
Table 2 Thermodynamic stability constants log KML for non-protonated complexes with divalent metals, determined at 25 °C in NaCl, I = 0.15 M.
Data have been obtained using UV/Vis spectroscopy (a), potentiometry (b), or NMR (c). Literature data for potentiometry in Me4NCl, I = 0.1 M, are
shown for comparison. Stepwise protonation constants of the complexes, as well as details on experimental procedures and UV/VIS or NMR signals
used for calculation, are given in the ESI
log KML for M
2+ + Lk−⇄ [ML](2−k)−
[M(TRAP(CHX)3)]
− [M(TRAP)]4− [M(NOTA)]−
NaCl NaCl Me4NCl
34 NaCl Me4NCl
34
Cu2+ 17.63(4)a 19.09(3)a 16.85 22.44(3)a 21.99
Zn2+ 15.15(6)b 16.07(3)b 16.88 21.56(5)c 21.58
15.75(5)c 16.39(6)c
Ca2+ 4.90(4)a 7.35(2)a 6.04 9.31(3) 10.32
Fig. 1 Pseudo-first-order rate constants at 25 °C (298 K) for the reac-
tion of CuII complexes of TRAP (empty symbols) and TRAP(CHX)3 (filled
symbols), with 10 (red), 20 (green) and 30 (blue) equivalents of EDTA
(squares) and NOTA (circles). Respective kd functions were calculated
from kinetic and equilibrium data.
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chain ligands can occur via concerted mechanisms with inter-
mediate formation of ternary complexes,53 dissociation of
metals from pendant-arm macrocycles is mostly governed by
stepwise mechanisms via formation of protonated
intermediates.54,55
In order to gain further insight into the underlying reaction
mechanisms and the species involved, pseudo-first-order rate
constants were measured at various temperatures over the
range of 288–323 K, and the Eyring activation parameters were
calculated for complex species with different protonation
states (Table 3, for details see the ESI†). As expected, a compari-
son of the rate constants at 298 K confirms that the formally
uncharged species [Cu(HTRAP(CHX)3)] and [Cu(H4TRAP))],
which most likely comprise pentacoordinate CuII and one non-
coordinating phosphinic acid donor group (Scheme 3), con-
tribute most to dissociation in acidic media. Since these
species are, according to their aforementioned protonation
constants in the range of 1.6 to 1.9, highly abundant at pH 1.5,
and their activation parameters are identical with respect to
the error margins (Table 3), the observed levelling of the
overall dissociation rate constants below pH 2 (Fig. 1) is well
explained.
The more the abundances of the deprotonated species [Cu-
(H3TRAP)]
− and [Cu(TRAP(CHX)3)]
− increase with increasing
pH, the more their individual dissociation rate constants
(Table 3) become relevant for the overall rates. Despite the rate
constant of [Cu(H3TRAP)]
− (6.2 × 10−5 s−1) being more than
one order of magnitude lower than that of the uncharged [Cu
(H4TRAP)] (2.1 × 10
−3 s−1), its contribution is substantial and
dominates dissociation of Cu(TRAP) above pH 3.5 (Fig. 2). In
contrast, the rate constant for the corresponding [Cu(TRAP
(CHX)3)]
− (7 × 10−7 s−1) is so low that its contribution is negli-
gible up to pH 4, which explains the observed divergence of
overall dissociation rates for Cu(TRAP) and Cu(TRAP(CHX)3)
above pH > 2.5 (Fig. 1) and, therefore, the increased inertness
of the conjugate complexes.
The pH-dependent half lives of dissociation, calculated and
extrapolated on the basis of equilibrium and kinetic data,
finally allow us to draw some important conclusions. Fig. 3
illustrates that functionalisation of TRAP results in the signifi-
cantly increased kinetic inertness of the corresponding CuII
complexes above pH 2. Furthermore, removal of CuII from
Scheme 3 Proposed mechanism for the proton-assisted dissociation of CuII–TRAP complexes. The colored arrows indicate the structural
rearrangements occurring during the rate-determining step. The driving force of the entire reaction is a practically irreversible complexation of CuII
by an excess scavenger ligand (not shown).
Table 3 Rate constants at 298 K and Eyring activation parameters for the spontaneous dissociation (the first-order reaction) of CuII complexes (for
Eyring plots and calculations, see the ESI)
[Cu(H3TRAP)]
− [Cu(H4TRAP)] [Cu(HTRAP(CHX)3)] [Cu(TRAP(CHX)3)]
−
k298 K (s
−1) (6.2 ± 0.3) × 10−5 (2.1 ± 0.1) × 10−3 (2.2 ± 0.1) × 10−3 (7 ± 2) × 10−7
ΔH‡ (kJ mol−1) 77 ± 8 67 ± 3 69 ± 5 88 ± 10
ΔS‡ (J mol−1 K−1) −68 ± 10 −71 ± 8 −65 ± 10 −65 ± 30
ΔG‡298 K (kJ mol−1) 97.2 88.2 88.3 108
Fig. 2 Contributions of the spontaneous dissociation of the different
Cu(TRAP) complexes to the overall, pH-dependent reaction rate. In this
pH range, the curve for [Cu(HTRAP(CHX)3)] (dotted line) is equivalent to
the overall rate for Cu(TRAP(CHX)3) (see Fig. 1), as it is the only contri-
buting species.
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TRAP conjugates is best performed at pH 2–3, where τ1/2 is
sufficiently short to achieve complete demetallation overnight
at r.t., or within a few hours at elevated temperatures. On the
other hand, an extrapolated τ1/2 of >100 h for Cu(TRAP(CHX)3)
at pH 7 and at body temperature strongly corroborates the
general suitability of TRAP conjugates for 64Cu-PET imaging.56
Application
During kinetic measurements, CuII transchelation to EDTA
was found incomplete (ca. 90%). This is not surprising
because the thermodynamic and conditional stability of the
CuII–EDTA complexes is comparably low (log KML = 19.02(3),
3.15(1), and 2.04(1) were measured for [Cu(EDTA)]2−,
[Cu(HEDTA)]− and [Cu(H2EDTA)]), resulting in partial dis-
sociation of Cu(EDTA) at pH 2–3, similar to Cu(TRAP)). Hence,
EDTA is only suitable for demetallation when applied in a very
high stoichiometric excess. Notwithstanding this, CuII could
be completely removed from Cu(TRAP(CHX)3) by means of dia-
filtration (continuous ultrafiltration),32 using a 1 mM solution
of H4EDTA (pH 2.8) as the running buffer, because this
approach allowed for successive removal of Cu(EDTA) from the
equilibrium.
Despite being considerably more expensive, NOTA was
identified as the reagent of choice for removal of CuII from
TRAP conjugates, owing to two important characteristics
which efficiently suppress the back reaction of the transchela-
tion equilibrium. First, its CuII complex is considerably more
stable than Cu(EDTA) or any CuII–TRAP complex (Table 2), pro-
viding a strong driving force for the entire reaction. Second,
the protonated complex [Cu(HNOTA)] is kinetically inert,52
meaning that it does not show a tendency towards spon-
taneous dissociation like Cu(EDTA) or the phosphinate com-
plexes. We found that demetallation of CuII-containing TRAP
conjugates could be achieved by adding NOTA directly to the
reaction mixture and adjusting the pH to 2–3 with dilute HCl,
once the click coupling is finished. In practice, addition of
NOTA trihydrochloride has been found to be most convenient,
since the NOTA-bound HCl readily adjusts the pH of the solu-
tion to the required acidic range, obviating the need for any
further reagent. Altogether, the favorable properties of NOTA
justify its application despite the high price, as this is of
secondary importance in view of the micromolar amounts of
substrates commonly handled during synthesis of precursors
for radiolabelling.
In order to demonstrate the utility and convenience of the
devised one-pot procedure, it was applied for the synthesis of a
trimeric conjugate of DUPA-Pep which otherwise would have
been much more difficult to obtain (Scheme 4). DUPA-Pep57 is
a urea-type enzyme inhibitor which has earlier been labelled
with 99mTc and used for in vivo SPECT imaging of prostate-
specific membrane antigen (PSMA, EC 3.4.17.21, synonyms:
glutamate carboxypeptidase II, NAALADase),58 a hydrolytic
zinc enzyme that is overexpressed by human prostate
cancers.59 For trimerisation, a terminal azide was introduced
by standard peptide coupling in solution, using pre-activated
5-azidopentanoic acid as the building block. Now, the trimer
was synthesised by applying our two-step, one-pot procedure
(Scheme 4). Conjugation and demetallation were virtually
quantitative according to HPLC/MS; unfortunately, final HPLC
purification considerably decreased the overall yield.
Notwithstanding this, a comparison of in vitro and in vivo
data for GaIII-complexes of TRAP(DUPA-Pep)3 and DOTAGA-
DUPA-pep (Scheme 5), a structurally related monomeric chela-
tor conjugate synthesised as a reference, demonstrated the
possible advantages of trimeric conjugates over the corres-
ponding monomers. Affinities to PSMA were determined by
cellular displacement assays on LNCaP cells (human prostate
carcinoma). IC50 values of 36 ± 4 nM and 2 ± 0.1 nM for the
monomer and the trimer, respectively, translate to an impress-
ive 18-fold increase in affinity.
PET images were acquired for both 68Ga-labelled com-
pounds, with CD-1 athymic nude mice bearing LNCaP xeno-
grafts on the right shoulder as subjects. Fig. 4 shows that
trimerisation resulted in substantially increased tumor uptake,
accompanied by a lower background. However, in this particu-
lar case, the increased tumor-to-background ratio most prob-
ably does not only rely on improved target affinity. According
to the recent literature, the poor performance of the monomer
is owing to degradation of DUPA-Pep in vivo, which, in turn, is
rooted in metabolic instability of the L-Phe–L-Phe structural
motif.60 Interconnection of several of these unstable moieties
in 68Ga-TRAP(DUPA-Pep)3 most likely results in a prolonged
time for complete loss of targeting properties of the entire con-
struct, as more than one metabolic cleavage per radiolabel is
required. This might be the reason for the superior retention
of activity at the target, observed for 68Ga-TRAP(DUPA-Pep)3.
This finding is of particular interest, because it suggests that it
Fig. 3 Dissociation half lives as functions of pH (τ1/2 = ln 2/kd, see also
ESI, eqn (18) and (23)†). An extrapolation is shown for Cu(TRAP(CHX)3) at
37 °C and above pH 4.
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might be generally possible to obtain useful (radio)pharmaceu-
ticals from metabolically unstable targeting molecules by
means of multimerisation. However, confirmation of this
hypothesis certainly requires more such multimers as
examples, the synthesis of which could be greatly facilitated
using the TRAP platform and applying our one-pot click chem-
istry protocol.
Scheme 4 Synthesis of TRAP(DUPA-Pep)3 for
68Ga-labelling and subsequent in vivo mapping of PSMA expression using PET.
Scheme 5 68Ga-DOTAGA-DUPA-Pep, a PSMA-targeting 68Ga-radio-
pharmaceutical used as the reference monomer.
Fig. 4 PET images (maximum intensity projections) of CD-1 athymic
nude mice bearing LNCaP tumor xenografts on the right shoulder,
acquired 90 min after injection of 68Ga-DOTAGA-DUPA-Pep (left) and
68Ga-TRAP(DUPA-Pep)3 (right). Tumor positions are indicated by arrows.
High activity uptake in kidneys and bladder (denoted bl.) is owing to
physiological PSMA expression and/or excretion. The high background
level in the left image is caused by unspecific distribution of activity due
to metabolic instability of 68Ga-DOTAGA-DUPA-Pep.60
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Conclusion
The opposing trends of thermodynamic stability and kinetic
inertness, observed for the CuII complexes of TRAP and TRAP-
conjugates, are another example for the generally known but
frequently unheeded fact that equilibrium constants are of
little predictive value concerning kinetic inertness, and thus,
in vivo stability, of metal complexes. For example, similar
observations have been described recently for CuII complexes
of cyclam-based diphosphinates and diphosphonates.61 We
would thus like to emphasise again that for a valid interpret-
ation or prognosis of in vivo behaviour, investigation of funda-
mental kinetics is of key importance. In addition, our results
illustrate that modifications on remote functional groups (i.e.,
conjugation sites) of a given bifunctional chelator can signifi-
cantly affect the metal-binding properties of its primary
coordination site.
In this respect, our data corroborate and explain a previous
study on the stability of some 64Cu-labelled TRAP-type chela-
tors, which showed that the 64CuII complex of a TRAP-peptide
trimer is much more stable upon challenging with aq.
Na2EDTA (pH 4.5) than that of neat TRAP (85% vs. 50% of
intact chelate, respectively, after 12 h).56 However, it should
not be disregarded that particularly for 64CuII complexes,
mechanisms other than proton-assisted ones can contribute to
demetallation in vivo, for example, interaction with other
metal cations (transmetallation)62 or enzymatic cleavage,63
which further complicates the matter.
In summary, we devised a simple and convenient one-pot
procedure for synthesis of TRAP-based trimeric chelator conju-
gates by means of click chemistry. Using the frameworks
TRAP(alkyne)3 and TRAP(azide)3, the CuAAC reaction with
3.3 eq. of a biomolecule with the respective opposite Huisgen
functionality, 1.2 eq. of CuII, and excess sodium ascorbate
quickly affords the trimer. This can easily be demetallated by
addition of excess NOTA trihydrochloride, owing to the pro-
nounced thermodynamic stability and kinetic inertness of the
CuII–NOTA complex. At this stage, it is worth noting that intro-
duction of azide functions to peptides on solid supports is not
only feasible by using commercially available building blocks,
such as 5-azidopentanoic acid, as shown above. The recently
described direct conversion of the N-terminus of a resin-bound
peptide into an azide64 ideally complements our method, paving
the way towards rapid access to trimeric peptidic radiopharma-
ceuticals. The prediction that such structures will frequently
exhibit enhanced target affinity and improved imaging pro-
perties, as exemplified in this study, appears justified in view of
the wealth of pertinent experience with multimerised targeting
vectors.35,44,57,65–71
Experimental
A complete and detailed description of Materials and methods
is provided in the ESI,† while a brief account is given
here. TRAP32 was prepared as described. TRAP(CHX)3,
32
TRAP(alkyne)3
35 and TRAP(azide)3 were prepared according to
a published procedure,32 by employing a modified peptide
coupling protocol (reagent: HATU, base: DIPEA, solvent:
DMSO) and the respective amines (cyclohexylamine, propargy-
lamine, 3-azidopropylamine). DOTAGA-DUPA-Pep was pre-
pared from commercial DUPA-Pep and decorated with
DOTAGA using DOTAGA-anhydride.72
Equilibrium studies (protonation and stability constants)
were performed by pH-potentiometry, UV-spectrophotometry,
and 1H- and 31P-NMR spectroscopy in 0.15 M NaCl. Rates of
ligand exchange reactions were determined for 0.2 mM solu-
tions of Cu(TRAP) and Cu(TRAP(CHX)3) by monitoring the for-
mation of Cu(NOTA) and Cu(EDTA) with UV-spectrophotometry
at 263 and 243 nm, at temperatures of 15, 25, 37, and 50 °C,
and pH values in the range of 1.5–4, which were kept constant
using dichloroacetic acid (DCA) (pH range 1.5–2.5), chloro-
acetic acid (MCA) (pH range 2.5–3.5) and 1,4-dimethyl-
piperazine (DMP) (pH = 3.1–4.1) buffers (0.01 M). Pseudo-
first-order conditions were achieved by employing 10–30 eq. of
NOTA and 10–20 eq. of EDTA.
Non-radioactive GaIII complexes of DOTAGA-DUPA-Pep and
TRAP(DUPA-Pep)3 for determination of affinity were prepared
by adding 2 mM gallium nitrate (0.5 mL) to the same volume of
2 mM solutions of the conjugates. Complete complex formation
occurred immediately and was confirmed by ESI-MS. IC50 values
were determined by a cellular displacement assay on LNCaP
(human prostate carcinoma) cells, using the radioiodinated
urea-type PSMA inhibitor ([125I]I-BA)KuE for competition.60
68Ga labelling was performed using the non-processed
generator eluate (1 M HCl, pH adjusted to 2–3 with HEPES) of
a SnO2-based
68Ge/68Ga-generator (iThemba LABS, SA) with
subsequent purification of the radiopharmaceuticals by
solid-phase extraction, employing a fully automated module.44
This procedure is readily transferable to clinical settings.73
PET imaging was performed on a Siemens Inveon small
animal PET system as described.35 Approx. 12 MBq of
68Ga-DOTAGA-DUPA-Pep (≈0.3 nmol) or 68Ga-TRAP(DUPA-Pep)3
(≈0.15 nmol) respectively were administered to CD-1 athymic
nude mice bearing LNCaP xenografts on the right shoulder.
PET data were acquired 60 min p.i. for 15 min, and images were
reconstructed by using OSEM3D algorithm.
Acknowledgements
Financial support by the Deutsche Forschungsgemeinschaft
(grant #NO822/4-1 and SFB 824, project Z1), by the European
Union and the State of Hungary (co-financed by the European
Social Fund in the framework of TÁMOP 4.2.4. A/2-11-1-2012-
0001 ‘National Excellence Program’, grant #A2-MZPD-12-0038,
and by the Hungarian Scientific Research Found (OTKA
K109029 and K84291) is gratefully acknowledged. The authors
furthermore thank Prof. Markus Schwaiger (Department of
Nuclear Medicine, TUM) for providing laboratory space and
granting access to imaging devices; Sybille Reder, Markus
Mittelhäuser and Marco Lehmann for assistance with animal
Paper Dalton Transactions
Dalton Trans. This journal is © The Royal Society of Chemistry 2015
Pu
bl
ish
ed
 o
n 
05
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 N
or
th
 D
ak
ot
a S
ta
te
 U
ni
ve
rs
ity
 o
n 
25
/0
5/
20
15
 0
9:
12
:2
4.
 
View Article Online
PET; Prof. Ernő Brücher and Dávid Horváth (University of Deb-
recen) for their advice on equilibrium and kinetic measure-
ments; Simon Moosmang, Simon Schmid, Veronika Stiegler
and Anja Wacker for laboratory assistance.
References
1 T. Beyer, D. W. Townsend, T. Brun, P. E. Kinahan,
M. Charron, R. Roddy, J. Jerin, J. Young, L. Byars and
R. Nutt, J. Nucl. Med., 2000, 41, 1369–1379.
2 H. Herzog, Z. Med. Phys., 2012, 22, 281–298.
3 C. Rischpler, S. G. Nekolla, I. Dregely and M. Schwaiger,
J. Nucl. Med., 2013, 54, 402–415.
4 A. Drzezga, M. Souvatzoglou, M. Eiber, A. J. Beer, S. Fürst,
A. Martinez-Möller, S. G. Nekolla, S. Ziegler, C. Ganter,
E. J. Rummeny and M. Schwaiger, J. Nucl. Med., 2012, 53,
845–855.
5 D. Razansky, N. C. Deliolanis, C. Vinegoni and V. Ntziachristos,
Curr. Pharm. Biotechnol., 2012, 13, 504–522.
6 C. Darne, Y. J. Lu and E. M. Sevick-Muraca, Phys. Med. Biol.,
2014, 59, R1–R64.
7 Y. D. Xu, H. G. Liu and Z. Cheng, J. Nucl. Med., 2011, 52,
2009–2018.
8 P. T. K. Chin, M. M. Welling, S. C. J. Meskers,
R. A. V. Olmos, H. Tanke and F. W. B. van Leeuwen,
Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 1283–1291.
9 L. M. Nie and X. Y. Chen, Chem. Soc. Rev., 2014, 43, 7132–
7170.
10 M. A. Deri, B. M. Zeglis, L. C. Francesconi and J. S. Lewis,
Nucl. Med. Biol., 2013, 40, 3–40.
11 T. Wadas, E. H. Wong, G. R. Weisman and C. J. Anderson,
Chem. Rev., 2010, 110, 2858–2902.
12 C. Decristoforo, R. D. Pickett and A. Verbruggen,
Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, S31–S40.
13 J. Notni, Nachr. Chem., 2012, 60, 645–649.
14 M. W. Greene and W. D. Tucker, Int. J. Appl. Radiat. Isot.,
1961, 12, 62–63.
15 C. Loc’h, B. Maziere and D. Comar, J. Nucl. Med., 1980, 21,
171–173.
16 J. Schuhmacher and W. Maier-Borst, Int. J. Appl. Radiat.
Isot., 1981, 32, 31–36.
17 K. Zhernosekov, M. Harfensteller, J. Moreno, O. Leib,
O. Buck, A. Tuerler, R. Henkelmann and T. Nikula,
Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, S251.
18 E. de Blois, H. S. Chan, C. Naidoo, D. Prince,
E. P. Krenning and W. A. P. Breeman, Appl. Radiat. Isot.,
2011, 69, 308–315.
19 S. Boschi, F. Lodi, C. Malizia, G. Cicoria and M. Marengo,
Appl. Radiat. Isot., 2013, 76, 38–45.
20 Z. Baranyai, F. Uggeri, A. Maiocchi, G. B. Giovenzana,
C. Cavallotti, A. Takács, I. Tóth, I. Bányai, A. Bényei,
E. Brücher and S. Aime, Eur. J. Inorg. Chem., 2013, 147–162.
21 J. Schuhmacher, G. Klívenyi, W. E. Hull, R. Matys,
H. Hauser, H. Kalthoff, W. H. Schmiegel, W. Maier-Borst
and S. Matzku, Nucl. Med. Biol., 1992, 19, 809–824.
22 E. Boros, C. L. Ferreira, J. F. Cawthray, E. W. Price,
B. O. Patrick, D. W. Wester, M. J. Adam and C. Orvig, J. Am.
Chem. Soc., 2010, 132, 15726–15733.
23 G. Tircsó, E. T. Benyó, E. H. Suh, P. Jurek, G. E. Kiefer,
A. D. Sherry and Z. Kovács, Bioconjugate Chem., 2009, 20,
565–575.
24 C. L. Ferreira, D. T. T. Yapp, D. Mandel, R. K. Gill, E. Boros,
M. Q. Wong, P. Jurek and G. E. Kiefer, Bioconjugate Chem.,
2012, 23, 2239–2246.
25 J. Notni, K. Pohle, J. A. Peters, H. Görls and C. Platas-
Iglesias, Inorg. Chem., 2009, 48, 3257–3267.
26 K. P. Eisenwiener, M. I. M. Prata, I. Buschmann,
H. W. Zhang, A. C. Santos, S. Wenger, J. C. Reubi and
H. R. Mäcke, Bioconjugate Chem., 2002, 13, 530–541.
27 A. N. Singh, W. Liu, G. Hao, A. Kumar, A. Gupta, O. K. Oz,
J.-T. Hsieh and X. Sun, Bioconjugate Chem., 2011, 22, 1650–
1662.
28 F. L. Guerra Gomez, T. Uehara, T. Rokugawa, Y. Higaki,
H. Suzuki, H. Hanaoka, H. Akizawa and Y. Arano, Bioconju-
gate Chem., 2012, 23, 2229–2238.
29 J. Šimeček, J. Notni, T. G. Kapp, H. Kessler and
H. J. Wester, Mol. Pharm., 2014, 11, 1687–1695.
30 J. Šimeček, O. Zemek, P. Hermann, J. Notni and
H. J. Wester, Mol. Pharm., 2014, 11, 3893–3903.
31 J. Notni, J. Šimeček and H. J. Wester, ChemMedChem, 2014,
9, 1107–1115.
32 J. Notni, P. Hermann, J. Havlíčková, J. Kotek, V. Kubíček,
J. Plutnar, N. Loktionova, P. J. Riss, F. Rösch and I. Lukeš,
Chem. – Eur. J., 2010, 16, 7174–7185.
33 (a) J. Šimeček, J. Notni, V. Kubíček and P. Hermann, Nucl.
Med. Biol., 2010, 37, 679; (b) J. Notni, J. Šimeček,
P. Hermann and H. J. Wester, J. Labelled Compd. Radio-
pharm., 2011, 54, S407.
34 J. Šimeček, M. Schulz, J. Notni, J. Plutnar, V. Kubíček,
J. Havlíčková and P. Hermann, Inorg. Chem., 2012, 51, 577–
590.
35 J. Notni, J. Šimeček, P. Hermann and H. J. Wester, Chem.
– Eur. J., 2011, 17, 14718–14722.
36 J. Notni, K. Pohle and H. J. Wester, EJNMMI Res., 2012, 2,
28.
37 J. Šimeček, P. Hermann, H. J. Wester and J. Notni, Chem-
MedChem, 2013, 8, 95–103.
38 J. Notni, P. Hermann, I. Dregely and H. J. Wester, Chem.
– Eur. J., 2013, 19, 12602–12606.
39 J. Notni, P. Hermann, I. Dregely and H. J. Wester, J. Labelled
Compd. Radiopharm., 2013, 56, S62.
40 J. Notni, P. Hermann, I. Dregely, M. Schwaiger and
H. J. Wester, Eur. J. Nucl. Med. Mol. Imaging, 2013, 40,
S229.
41 J. Notni, J. Plutnar and H. J. Wester, EJNMMI Res., 2012, 2,
13.
42 V. V. Rostovtsev, L. G. Green, V. V. Fokin and
K. B. Sharpless, Angew. Chem., Int. Ed., 2002, 41, 2596–
2599.
43 E. Kriemen, E. Ruf, U. Behrens and W. Maison, Chem.
– Asian J., 2014, 9, 2197–2204.
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2015 Dalton Trans.
Pu
bl
ish
ed
 o
n 
05
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 N
or
th
 D
ak
ot
a S
ta
te
 U
ni
ve
rs
ity
 o
n 
25
/0
5/
20
15
 0
9:
12
:2
4.
 
View Article Online
44 J. Notni, K. Pohle and H. J. Wester, Nucl. Med. Biol., 2012,
39, 777–784.
45 J. Notni, R. Braren, A. J. Beer, K. Steiger, A. Schlitter,
I. Esposito, J. Siveke, M. Erkan, M. Schwaiger and
H. J. Wester, Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, S131.
46 V. Kubíček, J. Havlíčková, J. Kotek, G. Tircsó, P. Hermann,
É. Tóth and I. Lukeš, Inorg. Chem., 2010, 49, 10960–10969.
47 (a) G. J. Stasiuk and N. J. Long, Chem. Commun., 2013, 49,
2732–2746; (b) N. Viola-Villegas and R. P. Doyle, Coord.
Chem. Rev., 2009, 253, 1906–1925.
48 B. Drahoš, V. Kubíček, C. S. Bonnet, P. Hermann, I. Lukeš
and É. Tóth, Dalton Trans., 2011, 40, 1945–1951.
49 K. Kumar, C. A. Chang, L. C. Francesconi, D. D. Dischino,
M. F. Malley, J. Z. Gougoutas and M. F. Tweedle, Inorg.
Chem., 1994, 33, 3567–3575.
50 E. Prenesti, P. G. Daniele, S. Berto and S. Toso, Polyhedron,
2006, 25, 2815–2823.
51 S. Pant, M. T. W. Hearn and K. Saito, Aust. J. Chem., 2010,
63, 502–506.
52 A. C. Bényei, Cambridge Crystallographic Data Centre
(CCDC) database entry #1025548, 2014.
53 J. F. Morfin and É. Tóth, Inorg. Chem., 2011, 50, 10371–
10378.
54 P. Lubal, M. Kývala, P. Hermann, J. Holubová, J. Rohovec,
J. Havel and I. Lukeš, Polyhedron, 2001, 20, 47–55.
55 I. Voráčová, J. Vaněk, J. Pasulka, Z. Střelcová, P. Lubal and
P. Hermann, Polyhedron, 2013, 61, 99–104.
56 J. Šimeček, H. J. Wester and J. Notni, Dalton Trans., 2012,
41, 13803–13806.
57 S. A. Kularatne, K. Wang, H.-K. R. Santhapuram and
P. S. Low, Mol. Pharm., 2009, 6, 780–789.
58 J. R. Mesters, C. Barinka, W. Li, T. Tsukamoto, P. Majer,
B. S. Slusher, J. Konvalinka and R. Hilgenfeld, EMBO J.,
2006, 25, 1375–1384.
59 (a) A. Ghosh and W. D. Heston, J. Cell. Biochem., 2004, 91,
528–539; (b) D. A. Silver, I. Pellicer, W. R. Fair,
W. D. Heston and C. Cordon-Cardo, Clin. Cancer Res., 1997,
3, 81–85.
60 M. Weineisen, J. Šimeček, M. Schottelius, M. Schwaiger
and H. J. Wester, EJNMMI Res., 2014, 4, 36.
61 M. Paúrová, J. Havlíčková, A. Pospíšilová, M. Vetrík,
I. Císařová, H. Stephan, H.-J. Pietzsch, M. Hruby,
P. Hermann and J. Kotek, Chem. – Eur. J., 2015, 21, 4671–
4687.
62 V. Maheshwari, J. L. J. Dearling, S. T. Treves and
A. B. Packard, Inorg. Chim. Acta, 2012, 393, 318–323.
63 K. Zarschler, M. Kubeil and H. Stephan, RSC Adv., 2014, 4,
10157–10164.
64 M. B. Hansen, T. H. M. van Gurp, J. C. M. van Hest and
D. W. P. M. Löwik, Org. Lett., 2012, 14, 2330–2333.
65 H. Kessler, M. Schudok and A. Haupt, in Peptides 1988
(Proc. 20th Europ. Pept. Symp., Sept. 4–9, 1988, Tübingen),
ed. G. Jung and E. Bayer, Walter de Gruyter, Berlin,
New York, 1989, 664–666.
66 H. J. Wester and H. Kessler, J. Nucl. Med., 2005, 46, 1940–
1945.
67 G. Thumshirn, U. Hersel, S. L. Goodman and H. Kessler,
Chem. – Eur. J., 2003, 9, 2717–2725.
68 C. Wängler, S. Maschauer, O. Prante, M. Schäfer,
R. Schirrmacher, P. Bartenstein, M. Eisenhut and
B. Wängler, ChemBioChem, 2010, 11, 1–15.
69 B. C. Lee, B. S. Moon, J. S. Kim, J. H. J. H. S. Park,
J. A. Katzenellenbogen and S. E. Kim, RSC Adv., 2013, 3,
782–792.
70 I. Dijkgraaf, C. B. Yim, G. M. Franssen, R. C. Schuit,
G. Luurtsem, S. Liu, W. J. G. Oyen and O. C. Boerman,
Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 128–137.
71 T. Poethko, M. Schottelius, G. Thumshirn, U. Hersel,
M. Herz, G. Henriksen, H. Kessler, M. Schwaiger and
H. J. Wester, J. Nucl. Med., 2004, 45, 892–902.
72 C. Bernhard, M. Moreau, D. Lhenry, C. Goze, F. Boschetti,
Y. Rousselin, F. Brunotte and F. Denat, Chem. – Eur. J.,
2012, 18, 7834–7841.
73 A. Al-Ibraheem, R. A. Bundschuh, J. Notni, A. Buck,
A. Winter, H. J. Wester, M. Schwaiger and K. Scheidhauer,
Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 2005–2013.
Paper Dalton Transactions
Dalton Trans. This journal is © The Royal Society of Chemistry 2015
Pu
bl
ish
ed
 o
n 
05
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 N
or
th
 D
ak
ot
a S
ta
te
 U
ni
ve
rs
ity
 o
n 
25
/0
5/
20
15
 0
9:
12
:2
4.
 
View Article Online
